###begin article-title 0
###xml 120 124 <span type="species:ncbi:10090">mice</span>
Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 224 227 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 299 302 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
Complement represents a crucial mediator of neuroinflammation and neurodegeneration after traumatic brain injury. The role of the terminal complement activation pathway, leading to generation of the membrane attack complex (MAC), has not been thoroughly investigated. CD59 is the major regulator of MAC formation and represents an essential protector from homologous cell injury after complement activation in the injured brain.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59a </italic>
###xml 37 40 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 69 71 69 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 136 138 136 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 171 173 171 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 317 345 317 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neurological Severity Score </italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
Mice deleted in the Cd59a gene (CD59a-/-) and wild-type littermates (n = 60) were subjected to focal closed head injury. Sham-operated (n = 60) and normal untreated mice (n = 14) served as negative controls. The posttraumatic neurological impairment was assessed for up to one week after trauma, using a standardized Neurological Severity Score (NSS). The extent of neuronal cell death was determined by serum levels of neuron-specific enolase (NSE) and by staining of brain tissue sections in TUNEL technique. The expression profiles of pro-apoptotic (Fas, FasL, Bax) and anti-apoptotic (Bcl-2) mediators were determined at the gene and protein level by real-time RT-PCR and Western blot, respectively.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 35 39 35 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 276 280 276 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 475 479 475 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 744 748 744 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
###xml 642 645 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 762 766 <span type="species:ncbi:10090">mice</span>
Clinically, the brain-injured CD59a-/- mice showed a significantly impaired neurological outcome within 7 days, as determined by a higher NSS, compared to wild-type controls. The NSE serum levels, an indirect marker of neuronal cell death, were significantly elevated in CD59a-/- mice at 4 h and 24 h after trauma, compared to wild-type littermates. At the tissue level, increased neuronal cell death and brain tissue destruction was detected by TUNEL histochemistry in CD59a-/- mice within 24 hours to 7 days after head trauma. The analysis of brain homogenates for potential mediators and regulators of cell death other than the complement MAC (Fas, FasL, Bax, Bcl-2) revealed no difference in gene expression and protein levels between CD59a-/- and wild-type mice.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 262 265 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
These data emphasize an important role of CD59 in mediating protection from secondary neuronal cell death and further underscore the key role of the terminal complement pathway in the pathophysiology of traumatic brain injury. The exact mechanisms of complement MAC-induced secondary neuronal cell death after head injury require further investigation.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 578 579 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 849 850 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 95 98 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 317 320 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 790 793 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
Clinical and experimental studies have implied a pivotal role for the membrane attack complex (MAC, C5b-9) of the terminal complement activation pathway in the pathogenesis of secondary neuronal cell death after traumatic brain injury [1-4]. The complement regulatory molecule CD59 represents the major controller of MAC formation and an essential protector of homologous cell injury after complement activation [5,6]. Neurons express CD59 constitutively to protect from autologous "innocent bystander" cell lysis after activation of the complement system in the injured brain [2,7]. However, due to low levels of neuronal CD59 expression, the neuronal capacity of controlling complement activation is very limited [7], which renders neurons susceptible to complement-mediated lysis by the MAC in the setting of intracerebral complement activation [8-10].
###end p 11
###begin p 12
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 520 521 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 239 242 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 416 419 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 501 506 <span type="species:ncbi:9606">human</span>
One of the putative mechanisms of complement-mediated neuronal death is reflected by the notion that the activation of phosphatidyl-inositol-specific phospholipase C (PI-PLC) after traumatic brain injury [11] renders neurons vulnerable to MAC-mediated lysis by shedding of the glycosyl-phosphatidyl-inositol (GPI)-anchored glycoprotein CD59 from neuronal membranes [2]. The intracerebral formation and deposition of MAC on neurons in the contusion area and penumbra zone has been shown to occur after human head injury [3,12]. However, the biological significance of CD59 in protecting from complement-mediated neuropathology after traumatic brain injury is far from being fully understood.
###end p 12
###begin p 13
###xml 152 158 152 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59a </italic>
###xml 164 167 164 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59 </italic>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59a </italic>
###xml 246 252 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59b </italic>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 290 294 290 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 497 505 497 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 677 681 677 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
The present study was designed to investigate the role of CD59a in a standardized experimental model of closed head injury in mice lacking the gene for Cd59a (CD59a-/-). In mice, the Cd59 gene is duplicated, yielding Cd59a (widely expressed) and Cd59b (testis-restricted) [13,14]. The CD59a-/- mice were previously shown to be highly susceptible to complement-mediated demyelination and axonal injury in a model of experimental allergic encephalomyelitis (EAE) [15], and thus provide an excellent in vivo model to investigate the role of complement-mediated membrane attack and CD59-dependent neuroprotection in the setting of traumatic brain injury. We hypothesized that CD59a-/- mice would be more susceptible to complement-mediated secondary brain injury than wild-type littermates in a standardized model of closed head injury.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
Animals
###end title 15
###begin p 16
###xml 44 48 44 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 256 260 256 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 407 411 407 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 944 954 938 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 967 969 961 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1009 1011 1003 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1027 1029 1021 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1039 1042 1033 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1128 1189 1122 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Federation of European Laboratory Animal Science Association </italic>
###xml 1260 1339 1254 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Landesamt f&#252;r Arbeitsschutz, Gesundheitsschutz und technische Sicherheit Berlin</italic>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
The generation and characterization of CD59a-/- mice was previously described [16]. These mice were found to have a spontaneous intravascular hemolysis due to erythrocyte susceptibility to complement-mediated lysis. Despite the chronic hemolysis, the CD59a-/- mice are healthy and fertile, not anemic, but display elevated reticulocyte counts as a indicator of increased erythrocyte turnover [16]. The CD59a-/- mice were generated on a mixed 129/Sv x C57BL/6 genetic background. Wild-type littermates of the 129/Sv x C57BL/6 strain were used as controls. All mice were of age 10-12 weeks, weighing 28-32 g, and of male gender exclusively, in order to avoid a bias regarding gender-related susceptibilty to brain injury. Animals were kept in single cages, bred in a selective pathogen-free (SPF) environment under standardized conditions of temperature (21degreesC), humidity (60%), light and dark cycles (12:12 h), with food and water provided ad libitum. A total of n = 134 animals were used for this study (n = 67 wild-type; n = 67 CD59a-/-). All experimental procedures were performed in compliance with the standards of the Federation of European Laboratory Animal Science Association (FELASA) and were approved by the institutional animal care committee (Landesamt fur Arbeitsschutz, Gesundheitsschutz und technische Sicherheit Berlin, Berlin, Germany; approval No. G0308/04).
###end p 16
###begin title 17
Surgical procedures
###end title 17
###begin p 18
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 421 424 417 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 654 658 648 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1107 1111 1101 1105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1586 1588 1580 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1589 1591 1583 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
###xml 548 552 <span type="species:ncbi:10090">mice</span>
###xml 658 662 <span type="species:ncbi:10090">mice</span>
###xml 1032 1036 <span type="species:ncbi:10090">mice</span>
Mice were subjected to experimental closed head injury using a standardized weight-drop device, as previously described [17]. In brief, after induction of isoflurane anesthesia, the skull was exposed by a longitudinal midline scalp incision. The head was fixed and a 250 g weight was dropped on the skull, inducing a focal blunt injury to the left hemisphere from a mean height of 1.7 +/- 0.51 cm (mean +/- SEM) for CD59a-/-, and 2.6 +/- 0.48 cm for wild-type mice, respectively. The difference in selected weight-drop heights between the knockout mice and wild-type littermates is due to the observed increased susceptibility to head injury in the CD59a-/- mice, leading to sudden posttraumatic death in initial validation experiments. We therefore titrated the falling height to achieve a similar extent of neurological impairment 1 h after trauma between the groups, based on the baseline posttraumatic NSS (see below). The 1 h NSS reflects the initial extent of head injury. Thus, the reduced weight-drop height in the knockout mice is an indirect sign of increased susceptibility to trauma in the CD59a-/- group, independent of the additional parameters assessed at later time-points. The stratification of cohorts according to the initial NSS at 1 h has been previously described in this model system as a feasible strategy to attain comparable injury severity between the groups at baseline. This notion is supported by recent studies in the same experimental system which demonstrated a correlation between injury severity determined on MRI with the NSS at 1 hour after trauma [18,19].
###end p 18
###begin p 19
###xml 66 68 66 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 408 410 408 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 461 489 461 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neurological Severity Score </italic>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
###xml 829 833 <span type="species:ncbi:10090">mice</span>
After trauma, all mice received supporting oxygenation with 100% O2 until fully awake. They were brought back to their cages and monitored at regular time intervals for up to 7 days. Posttraumatic analgesia was provided by injection of 0.1 mg/Kg buprenorphin s.c. immediately prior to the experimental procedure. The posttraumatic neurological impairment was assessed at defined time intervals after trauma (t = 1 h, 4 h, 24 h, and 7 days) using a standardized Neurological Severity Score (NSS), as described below. Sham-operated mice underwent identical procedures with regard to anesthesia, analgesia, and surgical scalp incision, but were not subjected to experimental head trauma. Normal mice were used as an additional internal negative control group and were kept under identical conditions as the trauma and sham-operated mice, but no anesthesia, analgesia, surgical and experimental procedures were performed.
###end p 19
###begin title 20
Sample harvesting procedures
###end title 20
###begin p 21
###xml 97 99 97 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
Ten mice per group and time-point were euthanized by decapitation under isoflurane anesthesia at t = 4 h, 24 h, and 7 days. Brains were immediately surgically removed, divided into left (injured) and right (contralateral/uninjured) hemispheres, snap-frozen in liquid nitrogen and stored at -80degreesC until analysis. In addition, serum samples were collected prior to decapitation by intracardiac puncture at identical time-points for determination of neuronal cell death markers by ELISA. Serum samples were collected in sterile tubes, centrifuged at 12,000 rpm at 4degreesC for 20 min, aliquoted and frozen at -80degreesC until analyzed.
###end p 21
###begin title 22
Neurological severity score (NSS)
###end title 22
###begin p 23
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 243 245 243 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
A previously characterized 10-parameter score was used for assessment of posttraumatic neurological impairment, as described elsewhere in detail [20]. The NSS was assessed in a blinded fashion by two different investigators at the time-points t = 1 h, 4 h, 24 h, and 7 days after trauma. The baseline NSS at 1 hour reflects the severity of the initial injury. The score comprises 10 individual parameters, including tasks on motor function, alertness, and physiological behavior, whereby one point is given for failure of the task, and no point for succeeding. A maximum NSS score of 10 points indicates severe neurological dysfunction, with failure of all tasks. A spontaneous recovery over time, for up to 4 weeks after trauma, is observed in this model system, as previously described [17,20,21].
###end p 23
###begin title 24
Quantification of neuron-specific enolase
###end title 24
###begin p 25
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 180 185 <span type="species:ncbi:9606">human</span>
###xml 287 292 <span type="species:ncbi:10090">mouse</span>
Serum levels of neuron-specific enolase (NSE), an established marker of neuronal cell death after head injury [22], were determined by a commercially available ELISA, specific for human NSE (Immuno-Biological Laboratories, Minneapolis, MN). Following confirmation of cross-reactivity of mouse NSE, samples were diluted 1:10 and analyzed by ELISA according to the manufacturer's protocol. Absorbance was read at 450 nm using a "SpectraMax 190" reader (Molecular Devices, Sunnyvale, CA). All samples were analyzed in duplicate and results were calculated from the means of duplicate sample analysis. The sensitivity of the assay was 1 pg/ml, and the standard curve was linear from 1 pg/ml to 140 pg/ml.
###end p 25
###begin title 26
Assessment of neuronal cell death
###end title 26
###begin p 27
###xml 119 127 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In Situ </italic>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 991 995 985 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
The terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) technique was applied, using the "Fluorescein In Situ Cell Death Detection Kit" (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instructions, to determine the extent of neuronal cell death in tissue sections, as previously described [23,24]. In brief, slides were dried for 30 min followed by fixation in 10% formalin solution at RT. After washing in PBS, sections were incubated in ice-cold ethanol-acetic acid solution (3:1), washed in PBS and incubated with 3% Triton X-100 solution for 60 min at RT for permeabilization. Slides were then incubated with the TdT-enzyme in reaction buffer containing fluorescein-dUTP for 90 min at 37degreesC. Negative control was performed using only the reaction buffer without TdT enzyme. Positive controls were performed by digesting with 500 U/ml DNase grade I solution (Roche). To preserve cells for comparison, slices were covered with Vectashield(R) mounting medium containing 4',6'-diamino-2-phenylindole (DAPI; Vector). All samples were evaluated immediately after staining using an "Axioskop 40" fluorescence microscope (Zeiss, Germany) at 460 nm for DAPI and 520 nm for TUNEL fluorescence. Data were analyzed by Alpha digi doc 1201 software (Alpha Innotech, San Leandro, CA).
###end p 27
###begin title 28
Real-time RT-PCR
###end title 28
###begin p 29
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 638 642 638 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 715 719 713 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 999 1003 994 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1166 1170 1159 1161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1222 1226 1213 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 204 210 <span type="species:ncbi:10090">murine</span>
Changes in the mRNA expression profiles of pro-apoptotic (Fas, FasL, Bax) and anti-apoptotic (Bcl-2) mediators were determined by semi-quantitative two-step real-time RT-PCR using commercially available, murine-specific primers (Qiagen, Hilden, Germany). The amplicon lengths were 136 bp for GAPDH (Qiagen No. 241012), 96 bp for Fas (Qiagen No. 241122), 109 bp for FasL (Qiagen No. 241194), 146 bp for Bax (Qiagen No. 241116), and 118 bp for Bcl-2 (Qiagen No. 241118). The detailed technique used in our laboratory was previously described [24,25]. In brief, the left brain hemispheres were homogenized as individual hemispheres in Qiazol(R) buffer (Qiagen). Total RNA was isolated and further purified using RNeasy(R) Mini-kits (Qiagen) and RNA concentrations were measured using a spectrophotometer (Bio-Rad, Munich, Germany). From each brain hemisphere, 2 mug RNA were reversely transcribed using random nonamer and oligo-dT16mer primers (Operon Biotechnologies, Cologne, Germany) with Omniscript(R) kits (Qiagen), according to the manufacturer's instructions. Real-time RT-PCR was performed using validated commercially available and custom designed primer-probe(R) sets (Qiagen) and optimized protocols on the Opticon(R) real-time PCR Detection System (Bio-Rad). For quantification of gene expression levels, GAPDH amplicons were generated and used as a "house-keeping" internal control gene. Relative gene expression levels were calculated in relation to the corresponding GAPDH gene expression levels.
###end p 29
###begin title 30
Western blotting
###end title 30
###begin p 31
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 574 578 571 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1921 1925 1912 1914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
###xml 168 173 <span type="species:ncbi:10090">mouse</span>
###xml 1311 1317 <span type="species:ncbi:9986">rabbit</span>
###xml 1323 1328 <span type="species:ncbi:10090">mouse</span>
###xml 1342 1348 <span type="species:ncbi:9986">rabbit</span>
###xml 1354 1359 <span type="species:ncbi:10090">mouse</span>
###xml 1374 1380 <span type="species:ncbi:9986">rabbit</span>
###xml 1386 1391 <span type="species:ncbi:10090">mouse</span>
###xml 1424 1429 <span type="species:ncbi:10090">mouse</span>
The protein levels of pro- and anti-apoptotic mediators were determined in homogenized mouse brains by Western blot analysis, as previously described [23,25]. Briefly, mouse brains were surgically removed under anesthesia, separated into left and right hemispheres, and immediately homogenized in lysis buffer (Sigma) containing 100 mM TRIS-HCl (pH 7.5), 150 mM NaCl, 0.5% sodium dodecyl sulfate (SDS), 0.5% Nonidet P-40, 10 mug/ml aprotinin, 10 mug/ml leupeptin, 5 mug/ml pepstatin, 1 mM phenyl-methyl-sulfonyl fluoride in deionized water, using an Ultra Turrax Homogenizer(R) (IKA Werke, Staufen, Germany). After 15 min centrifugation at 13,000 x g, the protein content of the supernatants was determined by commercially available colorimetric protein assay ("BCA Protein Assay", Pierce/Perbio Science, Bonn, Germany). A 60 mug sample of total protein was denatured in loading buffer and separated under reducing conditions on 10% (for Fas, FasL) or 12% (for Bax, Bcl-2) SDS-polyacrylamide gels in parallel with a broad range prestained SDS-PAGE protein standard (Bio-Rad, Munich, Germany). Proteins were then transferred to Protean BA 83 nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) by electroblotting (Bio-Rad). The blots were blocked overnight and then incubated with either polyclonal rabbit anti-mouse Fas (1:200), rabbit anti-mouse FasL (1:200), rabbit anti-mouse Bax (1:300), or monoclonal anti-mouse Bcl-2 (1:500) antibodies (Santa Cruz Biotechnology, Heidelberg, Germany), and with a monocloncal anti-beta-actin antibody (clone AC-15, Sigma) diluted 1:10,000, as internal control for ascertaining equal loading of the bands. After incubation with HRP-labelled secondary antibodies (Dako, Hamburg, Germany, and Santa Cruz Biotechnology, Heidelberg, Germany), diluted 1:5,000, antibody binding was visualized by a non-radioactive chemiluminescence technique using a commercially available ECL(R) Western blotting kit (Amersham Pharmacia Biotech, Freiburg, Germany). Equal transfer of proteins to the blotting membrane was confirmed by ponceau red staining (Sigma).
###end p 31
###begin title 32
Statistical analysis
###end title 32
###begin p 33
###xml 241 242 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 367 368 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical analysis was performed using commercially available software (SPSS 9.0 for Windowstrade mark). Differences in intracerebral gene expression levels and NSE serum levels between the groups were determined by the unpaired Student's t-test. The repeated measures analysis of variance (ANOVA) was used for assessing differences in neurological scores (NSS). A P-value < 0.05 was considered statistically significant.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
Neurological outcome
###end title 35
###begin p 36
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 471 473 471 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 768 772 768 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1206 1210 1206 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 1222 1226 1222 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1232 1234 1232 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1249 1250 1249 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
###xml 1001 1005 <span type="species:ncbi:10090">mice</span>
###xml 1226 1230 <span type="species:ncbi:10090">mice</span>
The assessment of of neurological tasks was performed by two investigators who were blinded about the treatment groups (Figure 1). Normal untreated mice ("nil") and sham-operated control mice displayed a normal behavior, with a range of NSS scores between 0-2 points in all control groups. In contrast, head-injured mice in both treatment groups had a siginifcantly increased NSS at all time-points assessed for up to 7 days after trauma, compared to the control groups (P < 0.05, repeated measures ANOVA; Figure 1). In the trauma cohorts, the baseline NSS at 1 h was titrated by adjusting the falling height of the weight-drop device (see methods section), in order to achieve a similar range of initial injury severity between wild-type (median levels 5.7) and CD59a-/- mice (median levels 6.1). A spontaneous, physiological neurological recovery was seen in both treatment groups over time, as reflected by a decreased NSS at 7 days compared to 1 h after TBI. By 7 days, the head-injured wild-type mice showed a significantly decreased NSS, compared to the knockout animals, implying a more severe neurological impairment in the absence of CD59a at one week after trauma (median levels 1.7 in wild-type vs. 3.4 in CD59a-/- mice; P < 0.05; Figure 1).
###end p 36
###begin p 37
###xml 60 64 60 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Neurological outcome after head injury in wild-type and CD59<sup>-/- </sup>mice</bold>
###xml 158 188 158 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">"Neurological Severity Score" </italic>
###xml 300 302 300 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 647 649 647 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 688 690 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 808 812 808 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 840 842 840 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 944 948 944 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 961 962 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1004 1008 1004 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1130 1132 1130 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 812 816 <span type="species:ncbi:10090">mice</span>
###xml 834 838 <span type="species:ncbi:10090">mice</span>
###xml 948 952 <span type="species:ncbi:10090">mice</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
Neurological outcome after head injury in wild-type and CD59-/- mice. The posttraumatic neurological impairment was determined by a standardized 10-parameter "Neurological Severity Score" (NSS) in normal untreated ("nil"), sham-operated, and head-injured mice from 1 h to 7 days after trauma (total: n = 134 mice). The neurological assessment was performed in a blinded fashion by two different investigators. A maximal score of 10 points corresponds to a severe neurological impairment, while a score of 0 points reflects normal behavior. The graph shows the resultant median levels of the groups at different time-points. Normal untreated mice (n = 7 per group) and sham-operated mice (n = 30 per group) had normal neurological scores ranging from 0-2 points, with no difference between wild-type and CD59a-/- mice. In head-injured mice (n = 30 per group), the baseline NSS was titrated to be in a similar range between head-injured and CD59a-/- mice at 1 h (P> 0.05). By 7 days after trauma, the CD59a-/- mice had a significantly worse outcome compared to wild-type littermates, as reflected by a significantly increased NSS (*P < 0.05, repeated measures ANOVA). TBI, traumatic brain injury; WT, wild-type.
###end p 37
###begin title 38
NSE serum levels
###end title 38
###begin p 39
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 212 216 212 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 386 390 386 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 456 460 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 552 554 552 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
The quantification of NSE levels in serum samples, as a standard marker of neuronal injury [22], revealed non-detectable levels (below the sensitivity of the ELISA at 1 pg/ml) in sham-operated wild-type and CD59a-/- mice, at all time-points assessed (Figure 2). In contrast, NSE serum levels were detectable in head-injured mice at 4 h and 24 h, but not at 7 days after trauma. In CD59a-/- mice, the mean NSE levels were significantly higher at 4 h (369.5 vs. 132.8 pg/ml) and 24 h (58.0 vs. 7.5 pg/ml) after trauma, compared to wild-type littermates (P < 0.05; Figure 2).
###end p 39
###begin p 40
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Serum levels of neuron-specific enolase (NSE), a marker of neuronal cell death</bold>
###xml 215 219 215 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 448 452 448 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 595 599 595 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 641 643 641 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 654 656 654 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 665 667 665 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 678 680 678 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 768 773 768 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59a</italic>
###xml 865 867 863 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 814 818 <span type="species:ncbi:10090">mice</span>
Serum levels of neuron-specific enolase (NSE), a marker of neuronal cell death. NSE protein levels were quantified in serum samples by ELISA, as described in the methods section. In sham-operated wild-type and CD59a-/- mice, NSE was not detectable in any sample at any time-point, i.e. below the sensitivity of the assay at 1 pg/ml. In contrast, NSE serum levels were significantly elevated at 4 h and 24 h after trauma, both in wild-type and CD59a-/- mice, compared to sham-operated controls. In addition, the NSE serum levels were significantly higher at both time-points in head-injured CD59a-/- mice, compared to wild-type littermates (*P < 0.05 for t = 4 h, **P < 0.05 for t = 24 h). This implies a greater extent of neuronal cell death in the genetic absence of Cd59a. NSE was not detectable in head-injured mice at 7 days. Data are shown as mean +/- SEM for n = 3 per group and time-point. TBI, traumatic brain injury; WT, wild-type.
###end p 40
###begin title 41
Neuronal cell death
###end title 41
###begin p 42
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 624 626 624 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 764 765 764 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 897 901 897 901 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1071 1072 1071 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1154 1158 1154 1158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1569 1573 1569 1573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1730 1731 1730 1731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1988 1990 1988 1990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1991 1993 1991 1993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2048 2049 2048 2049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 843 847 <span type="species:ncbi:10090">mice</span>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
###xml 1158 1162 <span type="species:ncbi:10090">mice</span>
###xml 1573 1577 <span type="species:ncbi:10090">mice</span>
As previously described for this experimental model [24,25], head-injured wild-type mice exhibited a massive destruction of their cortical neuronal layers at the contusion site, as determined by immunohistochemistry using a specific anti-NeuN Ab as a neuronal marker. Figure 3 depicts the different anatomic regions assessed in coronal brain tissue sections. The histological investigation of intracerebral cell death by TUNEL histochemistry revealed a dramatic increase in TUNEL-positive neurons in the injured left hemispheres of wild-type mice, from 4 hours to 7 days after trauma (Figure 4, representative stainings for t = 24 h). In accordance with previously published findings [23,24], TUNEL-positive neurons were detected within the contusion zone (Figure 4) and the hippocampus (data not shown) of the injured hemisphere of wild-type mice for up to 7 days after trauma. Head-injured CD59a-/- mice showed a massive increase in the extent of brain tissue destruction and TUNEL-positive cells around the contusion site and in the ipsilateral cortex at 24 h (Figure 4), for up to 7 days after trauma (data not shown). Sham-operated or untreated CD59-/- mice did not show any positive TUNEL signals in any brain section (data not shown). The immunohistochemical staining of adjacent brain sections by specific cell markers for neurons (anti-NeuN), astrocytes (anti-GFAP), microglia and infiltrating leukocytes (anti-CD11b), revealed that neurons were the predominant TUNEL-positive cell type in all sections taken from the injured hemispheres of wild-type and CD59a-/- mice. TUNEL-positive cells were furthermore confirmed as neurons by their typical cellular size, morphology, and position in typical neuronal layers (Figure 4). As previously described, TUNEL-positive cells and the extent of cortical tissue destruction were less apparent in the contralateral (right) hemisphere as compared to the injured (left) hemisphere at all time-points assessed after trauma, in both groups [23,24]. The representative microphotographs shown in Figure 3 were highly reproducible in all tissue sections and animals throughout this study.
###end p 42
###begin p 43
###xml 0 114 0 114 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematic depiction of the anatomic regions of interest in coronal brain tissue sections from injured mouse brains</bold>
###xml 102 107 <span type="species:ncbi:10090">mouse</span>
Schematic depiction of the anatomic regions of interest in coronal brain tissue sections from injured mouse brains. Closed head injury was applied to the left hemisphere, as described in detail in the methods section. The right (contralateral) hemisphere served as internal negative control. The anatomic regions representing the tissue sections analyzed by TUNEL histochemistry in figure 4, include: (1) Contusion site in the left hemisphere; (2) Hippocampus; (3) Remote cortex in the ipsilateral hemisphere.
###end p 43
###begin p 44
###xml 81 85 81 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Exacerbated brain tissue destruction and neuronal cell death in head-injured CD59<sup>-/- </sup>mice</bold>
###xml 295 299 294 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 863 867 862 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1239 1243 1238 1242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1419 1423 1418 1422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 867 871 <span type="species:ncbi:10090">mice</span>
###xml 1243 1247 <span type="species:ncbi:10090">mice</span>
###xml 1423 1427 <span type="species:ncbi:10090">mice</span>
Exacerbated brain tissue destruction and neuronal cell death in head-injured CD59-/- mice. Microphotographs show adjacent cryosections of 8 mum thickness of left (injured) brain hemispheres harvested at 24 h after closed head injury each from a representative wild-type (upper panel) and a CD59a-/- (lower panel) mouse. Cellular signals were visualized by fluorescence microscopy. The left columns represent the DAPI nuclear stain which reveals the cellular distribution and morphology of all cells present in the resultant sections. TUNEL histochemistry was performed on adjacent sections (right columns) to reveal the distribution and morphology of cell death. TUNEL-positive cells were mainly detected within the contusion zone of head-injured wild-type mice. In contrast, the number of TUNEL-positive cells was clearly augmented in the contusion zone of CD59a-/- mice, and remote cell death was detected in cortical layers of the ipsilateral hemisphere and in the hippocampus. Neurons were identified as the main cellular source of TUNEL-positive cell types by immunostaining of adjacent brain sections using anti-NeuN as primary antibody, a neuron-specific cell marker (bottom panels). Uninjured, i.e. sham-operated or untreated, CD59-/- mice did not show any positive TUNEL signals in brain sections (data not shown). These data imply an increased amount of cell death and tissue destruction in brain-injured CD59-/- mice, compared to wild-type animals. Original magnifications: 100x.
###end p 44
###begin title 45
Mediators of apoptosis
###end title 45
###begin p 46
###xml 236 240 236 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 248 250 248 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 293 295 293 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 325 327 325 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 369 370 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 578 580 578 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 595 596 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 617 621 617 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 758 760 758 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 775 776 775 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 877 881 877 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 976 977 976 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1004 1005 1004 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1127 1131 1127 1131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1359 1361 1359 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1391 1393 1391 1393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 1131 1135 <span type="species:ncbi:10090">mice</span>
Homogenized brain tissue samples were analyzed by real-time RT-PCR and Western blotting for gene and protein expression of Fas, FasL, Bax and Bcl-2. A significant upregulation of Fas mRNA was detected in head-injured wild-type and CD59a-/- mice at t = 4 h, compared to sham-operated controls (n = 6 per group and time-point, P < 0.05, unpaired Student's t-test; Figure 5). In addition, the gene for the mitochondrial ant-apoptotic mediator Bcl-2 was significantly upregulated in injured brains of wild-type mice, compared to sham-operated controls, at all time-points assessed (P < 0.05; Figure 5). Head-injured CD59a-/- mice showed a trend towards decreased Bcl-2 expression at all time-points after trauma, which however was not statistically significant (P > 0.05; Figure 5). No significant differences in Fas, FasL, Bax and Bcl-2 expression in brains of wild-type vs. CD59a-/- mice were detected at any time-point for up to 7 days after trauma, either at the gene (Figure 5) or protein level (Figure 6; representative Western blot experiments). However, Bax protein expression appeared to be moderately upregulated in CD59a-/- mice 4 h after trauma, when compared to wild-type littermates. The digital quantification of protein bands on Western blot membranes did not reveal any statistically significant differences between the groups at any time-point (n = 3 per group and time-point, P > 0.05; data not shown).
###end p 46
###begin p 47
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Regulation of intracerebral gene expression for apoptotic mediators</bold>
###xml 503 505 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 532 533 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 703 705 703 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 781 785 781 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 871 873 869 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 110 116 <span type="species:ncbi:10090">murine</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
Regulation of intracerebral gene expression for apoptotic mediators. Total RNA was extracted from homogenized murine brains (injured left hemispheres) at 4 h, 24 h, and 7 days after sham surgery or experimental head injury. Gene expression levels of Fas, FasL, Bax and Bcl-2 were determined by semi-quantitative two-step real-time RT-PCR, as described in the methods section. A significant induction of Fas gene expression was detected at 4 h in both trauma groups, compared to sham-operated controls (*P < 0.05, unpaired Student's t-test). In addition, head-injured wild-type mice showed a significant induction of Bcl-2 expression at all time-points after trauma, compared to sham-operated controls (*P < 0.05). No significant differences between head-injured wild-type and CD59a-/- mice were detected for any gene at any time-point. Data are shown as mean +/- SEM for n = 6 per group and time-point. TBI, traumatic brain injury; WT, wild-type.
###end p 47
###begin p 48
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Regulation of intracerebral protein levels of apoptotic mediators</bold>
###xml 534 536 530 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 106 112 <span type="species:ncbi:10090">murine</span>
###xml 164 169 <span type="species:ncbi:10090">mouse</span>
Regulation of intracerebral protein levels of apoptotic mediators. Western blot analysis was performed in murine brain homogenates (injured left hemispheres) using mouse-specific primary antibodies and detection by a non-radioactive chemoluminescence assay, as described in the methods section. Equal protein amounts (60 mug per lane) were loaded on SDS-PAGE and consistent loading and blotting was confirmed by ponceau staining (not shown) and control blotting with beta-actin. The Western blots shown in this are representative for n = 3 per experiment. No significant differences were seen between the groups at a qualitative (figure) or quantitative level (not shown). TBI, traumatic brain injury; WT, wild-type.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59a </italic>
###xml 256 259 256 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 459 463 459 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 754 758 754 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 825 826 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1099 1103 1099 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1167 1171 1167 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1394 1395 1394 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1509 1510 1509 1510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
###xml 968 972 <span type="species:ncbi:10090">mice</span>
###xml 1000 1004 <span type="species:ncbi:10090">mice</span>
###xml 1103 1107 <span type="species:ncbi:10090">mice</span>
###xml 1171 1175 <span type="species:ncbi:10090">mice</span>
###xml 1381 1385 <span type="species:ncbi:10090">mice</span>
The present study was designed to evaluate the role of the complement regulatory molecule CD59a in the posttraumatic neuropathology after experimental closed head injury in mice. We sought to test the hypothesis that mice deficient in the Cd59a gene (CD59a-/-) would display a significantly increased susceptibility to complement-mediated secondary brain injury with regard to the extent of posttraumatic neurological impairment and neuronal cell death. CD59a-/- mice had a significantly impaired neurological outcome 7 days after experimental closed head injury, compared to wild-type controls. This neurological deterioration occurred despite equal titration of initial severity of injury, as determined by a similar baseline NSS in wild-type and CD59a-/- mice 1 h after trauma (5.7 vs. 6.1 points, mean NSS at 1 h; Figure 1). Strikingly, the titrated weight drop falling height required to induce a similar severity of injury was significantly less in the knockout mice (1.7 cm) than in wild-type mice (2.6 cm), implying an intrinsically increased baseline susceptibility to brain injury in CD59a-/- mice. Aside from the clinical deterioration within 7 days, CD59a-/- mice also showed a significant exacerbation of neuronal cell loss in the injured brain, as determined by (a) increased serum levels of NSE - an established marker of neuronal cell death - compared to wild-type mice (Figure 2), and (b) increased neuronal cell death and brain tissue destruction in TUNEL histochemistry experiments (Figure 4).
###end p 50
###begin p 51
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 315 319 315 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 508 512 508 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 698 702 698 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1036 1040 1036 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 143 146 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
###xml 726 729 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 1040 1044 <span type="species:ncbi:10090">mice</span>
Since programmed cell death represents an important mechanism of secondary neuronal cell death after head injury, and since complement and the MAC have been associated with neuronal apoptosis [10,26,27], we sought to further investigate the expression of apoptotic mediators in injured brains of wild-type and CD59a-/- mice. Interestingly, there was no significant difference in intracerebral expression of pro- (Fas, FasL, Bax) or anti-apoptotic mediators (Bcl-2) at the gene and protein level between CD59a-/- and wild-type mice, at any time-point investigated after trauma (Figures 5 and 6). These findings suggest that the exacerbated induction of neuronal cell death in injured brains of CD59a-/- mice may reflect direct MAC-mediated cellular lysis in large part, as opposed to indirect cell death mechanisms by differential regulation of apoptotic mediators. However, this notion remains speculative and requires further investigation of the detailed, molecular mechanisms of posttraumatic neuronal cell loss in head-injured CD59a-/- mice.
###end p 51
###begin p 52
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 638 641 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
The complement system has been implicated for more than a decade in the pathophysiology of traumatic brain injury by contributing to neuroinflammation and secondary neuronal cell death [2]. However, the exact cellular and molecular mechanisms of complement-mediated neuropathology after head injury remain far from being fully understood. Recent studies have determined that all three activation pathways (i.e. classical, alternative, and lectin) are involved in the pathophysiology of posttraumatic complement activation in the injured brain [23,24,28,29]. Interestingly, the terminal complement pathway which leads to generation of the MAC (C5b-9), also termed the "killer molecule of complement" [30], has received less attention in recent research in the field of traumatic brain injury.
###end p 52
###begin p 53
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 676 685 676 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 895 902 895 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1029 1030 1029 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1220 1222 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 38 41 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 276 279 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 530 533 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 563 566 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 751 756 <span type="species:ncbi:9606">human</span>
###xml 861 864 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 934 937 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 1023 1027 <span type="species:ncbi:10090">mice</span>
###xml 1087 1091 <span type="species:ncbi:10116">rats</span>
###xml 1180 1183 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
We have previously shown that soluble MAC levels are significantly increased in the intrathecal compartment of patients with severe head injuries, and were associated with the extent of posttraumatic blood-brain barrier (BBB) dysfunction [3]. Other groups have shown that the MAC is a potent inducer of intracerebral neuropathology and neuroinflammation, by mediating the upregulation of adhesion molecules and leukocyte infiltration in the subarachnoid space and cerebral parenchyma within a few hours of intracerebroventricular MAC injection [31]. In addition, MAC injection into hippocampus was shown to evoke seizures and neurocytotoxicity [32]. A different study used an in vitro model of BBB damage and revealed that the co-incubation of normal human cerebrospinal fluid with normal serum from healthy donors resulted in complement activation and soluble MAC (sC5b-9) formation [33]. Mead et al. described a crucial role of the MAC in contributing to demyelination and axonal injury in studies of EAE in C6-deficient mice [9]. In a model of experimental weight-drop head injury in rats, complement C9 deposition was demonstrated around the cerebral contusion site, implying MAC deposition in injured brain tissue [34].
###end p 53
###begin p 54
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 388 394 388 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59a </italic>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 730 731 730 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1023 1028 1023 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59 </italic>
###xml 1076 1077 1076 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1078 1079 1078 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1080 1082 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1083 1085 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 82 85 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 248 251 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 268 273 <span type="species:ncbi:10090">mouse</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 427 432 <span type="species:ncbi:10090">mouse</span>
The complement regulatory molecule CD59 is a GPI-anchored molecule which controls MAC assembly in cellular membranes and thus protects from homologous cell lysis after complement activation [5]. CD59a has been described as the primary regulator of MAC assembly in the mouse, since mice have a testis-restricted CD59b expression [13]. We have recently described a significant induction of Cd59a gene upregulation in the injured mouse brains, using the same experimental closed head injury model as in the present study [25]. It appears that the upregulation of CD59a in injured brains represents a feedback mechanism aimed at protecting neurons from accidental homologous cell lysis related to posttraumatic complement activation [2]. However, in the complex setting of head injury-induced neuroinflammation, the shedding of the GPI-anchored glycoprotein CD59 from cell surfaces by activation of phospholipases, such as PI-PLC, may render neurons vulnerable to complement mediated attack, independent of upregulation of the Cd59 gene, as briefly described in the introduction [2,5,11,25].
###end p 54
###begin p 55
###xml 5 9 5 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd59a </italic>
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 66 74 66 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 258 262 258 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 489 493 489 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 519 522 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 562 565 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 891 894 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
CD59a-/- mice which lack the Cd59a gene [16] provide an excellent in vivo model to test the relevance of the terminal complement pathway in contributing to secondary neuropathology after traumatic brain injury. Recent experimental studies revealed that CD59a-/- mice are more susceptible to ischemia/reperfusion injuries [35] and to disease severity, myelin loss and axonal damage after EAE [15]. The latter study showed that areas of myelin loss and axonal damage in spinal cords of CD59a-/- mice were associated with MAC deposition, implicating the complement MAC as a crucial mediator of neuropathology of this autoimmune disease [15]. The findings of exacerbated neurological impairment and increased neuronal cell loss in our current study on experimental closed head injury concur with the previous findings in the EAE model [15] and further underline the importance of the complement MAC in the pathophysiology of inflammatory central nervous system (CNS) disorders.
###end p 55
###begin p 56
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 578 583 <span type="species:ncbi:9606">human</span>
###xml 657 662 <span type="species:ncbi:9606">human</span>
###xml 965 973 <span type="species:ncbi:9606">patients</span>
Traumatic brain injury is currently still lacking a specific pharmacological therapy designed to avoid induction of secondary brain injuries and delayed neuronal cell death [36]. However, in the field of therapeutic complement inhibitor development, there have been significant advances in recent years [37-40]. While some of these inhibitors have been successfully tested in experimental head injury models [24,25,41], the "bench-to-bedside" extrapolation to clinical applications in head injured patients has yet to be accomplished [36]. In this regard, the identification of human CD59 complement binding interfaces, as well as the recent development of human soluble mutant CD59-based compounds, which have been shown to exert an up to 3-fold increased complement inhibitory activity [42], may represent a promising future strategy for attenuating the terminal complement pathway-mediated neuropathology and the extent of secondary brain damage in head-injured patients.
###end p 56
###begin title 57
Competing interests
###end title 57
###begin p 58
###xml 71 204 71 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">"Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury, and related conditions</italic>
PFS is the co-inventor of a US patent filed (No. 11,441,828) entitled: "Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury, and related conditions." The authors declare no other potential conflict of interest related to this project.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
###xml 54 58 54 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
PFS and BPM designed the study. BPM provided the CD59a-/- mice and wild-type littermates. PFS and IL performed and supervised the animal experiments. MAF and BMT performed the ELISA experiments. IP, CS, CC, and IL performed the PCR and Western blot experiments. BPM, WRS, KB, OIS, and WE contributed to analysis and interpretation of the data and corrections of the manuscript. PFS and MAF wrote the first draft of the paper. All authors read and approved the final version of this manuscript.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
###xml 177 180 177 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 175 228 175 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">11<sup>th </sup>European Meeting on Complement in Human Diseases</italic>
###xml 214 219 <span type="species:ncbi:9606">Human</span>
This study was supported by the German Research Foundation (DFG) grants No. STA 635/2-1 and STA 635/2-2 to PFS, OIS, and WE. The project has been previously presented at the "11th European Meeting on Complement in Human Diseases" in Cardiff, Wales, UK, September 8-11, 2007. Parts of this work have been published in abstract form in the proceedings of this scientific meeting.
###end p 62
###begin article-title 63
Role of complement in inflammation and injury in the nervous system
###end article-title 63
###begin article-title 64
The role of the complement system in traumatic brain injury
###end article-title 64
###begin article-title 65
###xml 132 140 <span type="species:ncbi:9606">patients</span>
Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury
###end article-title 65
###begin article-title 66
The role of the complement system in CNS inflammatory diseases
###end article-title 66
###begin article-title 67
Regulation of the complement membrane attack pathway
###end article-title 67
###begin article-title 68
Alternative roles for CD59
###end article-title 68
###begin article-title 69
Differential expression of individual complement regulators in the brain and choroid plexus
###end article-title 69
###begin article-title 70
###xml 86 91 <span type="species:ncbi:9606">human</span>
Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis
###end article-title 70
###begin article-title 71
The membrane attack complex of complement causes severe demyelination associated with acute axonal injury
###end article-title 71
###begin article-title 72
Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis
###end article-title 72
###begin article-title 73
Increased phospholipase C activity after experimental brain injury
###end article-title 73
###begin article-title 74
###xml 29 34 <span type="species:ncbi:9606">human</span>
Complement activation in the human brain after traumatic head injury
###end article-title 74
###begin article-title 75
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
CD59a is the primary regulator of membrane attack complex assembly in the mouse
###end article-title 75
###begin article-title 76
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
The mouse complement regulator CD59b is significantly expressed only in testis and plays roles in sperm acrosome activation and motility
###end article-title 76
###begin article-title 77
###xml 107 113 <span type="species:ncbi:10090">murine</span>
Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis
###end article-title 77
###begin article-title 78
Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria
###end article-title 78
###begin article-title 79
###xml 47 51 <span type="species:ncbi:10090">mice</span>
An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits
###end article-title 79
###begin article-title 80
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions
###end article-title 80
###begin article-title 81
###xml 126 130 <span type="species:ncbi:10090">mice</span>
A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice
###end article-title 81
###begin article-title 82
###xml 165 169 <span type="species:ncbi:10090">mice</span>
Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines
###end article-title 82
###begin article-title 83
###xml 107 122 <span type="species:ncbi:10090">transgenic mice</span>
Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice
###end article-title 83
###begin article-title 84
Serum biomarker concentrations and outcome after pediatric traumatic brain injury
###end article-title 84
###begin article-title 85
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation
###end article-title 85
###begin article-title 86
###xml 167 171 <span type="species:ncbi:10090">mice</span>
Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice
###end article-title 86
###begin article-title 87
Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury
###end article-title 87
###begin article-title 88
Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells
###end article-title 88
###begin article-title 89
Effects of membrane attack complex of complement on apoptosis in experimental autoimmune encephalomyelitis
###end article-title 89
###begin article-title 90
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Reduced tissue damage and improved recovery of motor function after traumatic brain injury in mice deficient in complement component C4
###end article-title 90
###begin article-title 91
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Mannose binding lectin gene deficiency increases susceptibility to traumatic brain injury in mice
###end article-title 91
###begin article-title 92
The killer molecule of complement
###end article-title 92
###begin article-title 93
###xml 101 104 <span type="species:ncbi:10116">rat</span>
Intracerebroventricular injection of terminal complement complex causes inflammatory reaction in the rat brain
###end article-title 93
###begin article-title 94
Formation of complement membrane attack complex in Mammalian cerebral cortex evokes seizures and neurodegeneration
###end article-title 94
###begin article-title 95
###xml 92 95 <span type="species:ncbi:9606">man</span>
Complement activation in the central nervous system following blood-brain barrier damage in man
###end article-title 95
###begin article-title 96
###xml 120 123 <span type="species:ncbi:10116">rat</span>
Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat
###end article-title 96
###begin article-title 97
###xml 60 64 <span type="species:ncbi:10090">mice</span>
CD59a deficiency exacerbates ischemia-reperfusion injury in mice
###end article-title 97
###begin article-title 98
Pharmacology of traumatic brain injury - where is the "golden bullet"?
###end article-title 98
###begin article-title 99
Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease
###end article-title 99
###begin article-title 100
Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics
###end article-title 100
###begin article-title 101
Complement therapeutics: history and current progress
###end article-title 101
###begin article-title 102
The alternative pathway of complement in disease: opportunities for therapeutic targeting
###end article-title 102
###begin article-title 103
###xml 99 103 <span type="species:ncbi:10116">rats</span>
Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats
###end article-title 103
###begin article-title 104
###xml 18 23 <span type="species:ncbi:9606">human</span>
Insights into the human CD59 complement binding interface toward engineering new therapeutics
###end article-title 104

